Boston Scientific Corp: Form 10-Q for the period ended Mar 31, 2022
Filed with the SEC on May 5, 2022 and accepted by EDGAR at May 5, 2022, 16:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-01-01 to 2022-03-31 | $3.03bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-01-01 to 2022-03-31 | $955.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-01-01 to 2022-03-31 | $2.07bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-01-01 to 2022-03-31 | $1.06bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-01-01 to 2022-03-31 | $466.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-01-01 to 2022-03-31 | $279.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-01-01 to 2022-03-31 | $45.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-01-01 to 2022-03-31 | $110.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2022-01-01 to 2022-03-31 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-01-01 to 2022-03-31 | $0.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-01-01 to 2022-03-31 | 1,438,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-01-01 to 2022-03-31 | −$58.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-01-01 to 2022-03-31 | $121.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2022-01-01 to 2022-03-31 | $14.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2022-03-31 | $325.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-03-31 | $5.07bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-03-31 | $32.34bn | us-gaap:Assets |
| Current liabilities | At period end2022-03-31 | $4.28bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2022-03-31 | $238.0m | us-gaap:DebtCurrent |
Source: SEC EDGAR, the filing index for accession 0000885725-22-000013. Last ingested by Listed: Nov 6, 2026, 17:38 ET. Listed shows no prices and gives no investment advice.